Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
US-12447171-B2 · Oct 21, 2025 · US
This page is not indexed by search engines while we improve data quality.
Frattini Mark patents
Frattini Mark is listed as an inventor on 3 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | Frattini Mark |
| Total patents | 3 |
| First publication | Aug 11, 2022 |
| Latest publication | Oct 21, 2025 |
Notable patents
Publications ranked by popularity score, then publication date.
Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
US-2022249529-A1 · Aug 11, 2022 · US
Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome
US-2022249528-A1 · Aug 11, 2022 · US
Recent patents
Latest publications not already listed above.
No data yet.
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| Celgene Quanticel Res Inc | 2 |
| Celgene Corp | 1 |
Top CPC classifications
Most common classification codes across this inventor's patents.
| CPC | Patents |
|---|---|
| A61L2103/05 | 3 |
| A61L2/16 | 3 |
| A61K31/513 | 3 |
| A61K31/501 | 3 |
| A61K31/407 | 3 |